Discovery of substances to combat cancer drug resistance
December 2020
Martin Luther University Halle-Wittenberg, Halle, Germany
Multidrug resistance (MDR) is a widely known problem despite targeted cancer therapies and most patients who experience metastasic cancers die from MDR. The multidrug resistance proteins (MRP) are membrane pumps that pump the anticancer drug out of the cancer cells, thus making them resistant to medications. With the help of different human carcinoma cell lines, a new class of MRP inhibitors was developed which inactivates the pumps so the drug remains in the cancer cell. The findings offer potential new treatments of anticancer drug resistance.
Discovery of novel symmetrical 1,4-dihydropyridines as inhibitors of multidrug-resistant protein (MRP4) efflux pump for anticancer therapy
Andreas Hilgeroth
Added on: 04-30-2021
[1] www.mdpi.com/1420-3049/26/1/18/htm[2] https://www.bionity.com/en/news/1170177/new-inhibitor-found-to-combat-drug-resistant-cancer-cells.html
